RIA
ATOS icon

Richwood Investment Advisors’s Atossa Therapeutics ATOS Stock Holding History

Richwood Investment Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-40
Closed -$1K – 127
2021
Q4 		$1K Buy
+40
New +$1.46K ﹤0.01% 263

Other funds holding ATOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Richwood Investment Advisors's ATOS Position: Q1 2022 in Review

Richwood Investment Advisors sold out of Atossa Therapeutics (ATOS) in Q1 2022, closing a stake of 40 shares — an estimated $1K sold.

Richwood Investment Advisors first reported a position in ATOS in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 83 funds tracked by Wall St. Rank hold ATOS as of Q1 2022.

  • Richwood Investment Advisors reported no remaining Atossa Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Richwood Investment Advisors sold 40 Atossa Therapeutics shares in Q1 2022, an estimated $1K.
  • Richwood Investment Advisors first reported a position in Atossa Therapeutics in Q4 2021 and held it in 1 quarter.
  • Richwood Investment Advisors's Atossa Therapeutics position peaked at $1K in Q4 2021.
  • 83 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2022.

Based on Richwood Investment Advisors's 13F filing for Q1 2022, filed 28 Apr 2022.